Abstract
Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products.
Keywords: Immunoglobulin, infection, primary antibody deficiency, primary immunodeficiency diseases.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Volume: 16 Issue: 2
Author(s): Gholamreza Azizi, Hassan Abolhassani, Mohammad Hosein Asgardoon, Javad Rahnavard, Majid Zaki dizaji, Reza Yazdani, Javad Mohammadi and Asghar Aghamohammadi
Affiliation:
Keywords: Immunoglobulin, infection, primary antibody deficiency, primary immunodeficiency diseases.
Abstract: Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products.
Export Options
About this article
Cite this article as:
Azizi Gholamreza, Abolhassani Hassan, Asgardoon Hosein Mohammad, Rahnavard Javad, dizaji Zaki Majid, Yazdani Reza, Mohammadi Javad and Aghamohammadi Asghar, The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1871530316666160724214418
DOI https://dx.doi.org/10.2174/1871530316666160724214418 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Simple and Efficient Synthesis of Novel bis-Betti Bases via a One-Pot Pseudo-Five-Component Reaction
Letters in Organic Chemistry Sodium Carbonate Sesquiperhydrate (2Na2CO3-3H2O2) Catalysed One-pot Synthesis of Biologically Dynamic Novel Substituted Spirooxirane Dicarboxamides
Current Catalysis Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
Current Pharmaceutical Design Fish Oil Prevents Oxidative Stress and Exerts Sustained Antiamnesic Effect After Global Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Metabolism of Antiarrhythmics
Current Drug Metabolism Bioavailability Through PepT1: The Role of Computer Modelling in Intelligent Drug Design
Current Computer-Aided Drug Design Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Current Vascular Pharmacology Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Alpha-1 Adrenergic Antagonists Induced Severe Rhinitis in Patients with Benign Prostatic Hyperplasia
Current Drug Safety Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design State of the Art and Development of a Drug-Drug Interaction Large Scale Predictor Based on 3D Pharmacophoric Similarity
Current Drug Metabolism Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review
Current Neuropharmacology Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Difference in Blood Pressure Measurements Between Arms: Methodological and Clinical Implications
Current Pharmaceutical Design Vitamin E-Related Inhibition of Monocyte 5-Lipoxygenase and Cardiovascular Outcome in Maintenance Hemodialysis Patients
Recent Patents on Inflammation & Allergy Drug Discovery